The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Open accessAbstract
BACKGROUND: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders. METHODS: We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events. RESULTS: Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8). CONCLUSIONS: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Mutations in DNMT3A and TET2 account for over 90% of CH cases2,6”
From TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice (2025) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP has emerged as a clinically relevant state associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke [1,4,5].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, progression to hematological malignancies depends on the type and complexity of mutations in CHIP.2,5,6”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More important, advanced age is the best predictor of CHIP, with a 5.6% or 18.4% prevalence in the sixth or ninth decade of life, respectively.2”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are predicted to have high expansion rates (10% increase in mean VAF per year1, 2, 3,7)”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clone size, which is approximated by the variant allele fraction (VAF), has previously been shown to be an important predictor of risk for blood cancer1,17 and cardiovascular outcomes8,9.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Despite its hematologically silent nature, CH has been associated with increased mortality and morbidity [1,32].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“although increased red cell distribution width (RDW) has been reported (Jaiswal et al., 2014).”
From Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling (2021) · cites this paper as Jaiswal et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Instead, the discovery of widespread clonal expansions in ageing human tissues19,50–52 raises the possibility that some somatic mutations contribute to ageing by driving clonal expansions of functionally altered cells at a cost to the organism49,53,54.”
From Somatic mutation rates scale with lifespan across mammals (2022) · cites this paper as [50]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Methods adhered to published guidelines 77 .”
From Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice (2025) · cites this paper as [77]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The isolated effects of individual inflammatory cytokines, including type 1 interferons (IFNa/b) 1-3 , type 2 IFN (IFNg) 4-6 , TNFa 7,8 , and IL-1 9-11 , have been well-documented in mouse hematopoietic development.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Interestingly, while IFNa alters mouse HSC marker Sca-1 2 (rendering difficult the quantification of progenitor cell frequency changes by flow cytometric assessment in mice), IFNa did not alter CD90 expression after treatment in the HSPCs ( Fig. 2e, Supplementary Fig. 3c ).”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previously, induction of IFNa in mice have yielded mixed results demonstrating either an upregulation 2 or downregulation 53 of TNFa.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“clonal hematopoiesis is a frequent event in elderly people.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“Epigenetic genes that are relatively frequently affected in these conditions include DNMT3A, EZH2, TET2, and SETDB1.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“The phenomenon also appears to be counterintuitively well tolerated, where HSCs containing oncogenic mutations can overtake most of the hematopoietic system without transforming into leukemia (Jaiswal et al., 2014).”
From Unraveling Hematopoiesis through the Lens of Genomics (2020) · cites this paper as Jaiswal et al., 2014
In the citing paper
“The size of these mutant clones was massive; in one study, a median of ~18% of blood cells carried the mutations 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“For example, CHIP has been reported to be more common in older men 28 and smokers 27 and less common in Hispanics 28, although these associations are all relatively modest.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, in population-based cohorts that underwent exome sequencing, the presence of CHIP was associated with ~10-fold increased relative risk of these malignancies over several years of follow-up 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP itself does not denote a malignancy, nor is it associated with clinically significant alterations in blood counts 28,63.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In an initial study, this risk could not be explained by cancer deaths but was instead related to increased cardiovascular mortality 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In one study, 4% of CHIP carriers developed a blood cancer over the subsequent 8 years, corresponding to ~0.5% of CHIP cases converting to malignancy per year 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Several studies have found that CHIP is associated with a 30–40% increased mortality risk 27,28,37.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Myeloid malignancies were most common, although some people with CHIP did develop lymphoid cancers 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, some individuals with clonal hematopoiesis have virtually all of their blood cells arising from a single mutated HSC 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP has been found to be associated with a 30% increase in the likelihood of having type 2 diabetes (T2D) 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Studies of serial samples have shown that the trajectory of a clone can vary between people.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Some people have clones that remain stagnant in size for many years, whereas other people have clones that show steady growth 28,33.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Self-citationInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Cited by
Sorted by citations
Items 201–300 of 1,023
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Uckelmann, H. J., Kim, S. M., Wong, E. M. C., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., et al. (2020) · Science · doi:10.1126/science.aax5863 · Cited by 267
Myeloid cell contributions to cardiovascular health and disease
Nahrendorf, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0064-0 · Cited by 267
Guryanova, O. A., Shank, K., Spitzer, B., Luciani, L., Koche, R. P., Garrett-Bakelman, F. E., Ganzel, C., Durham, B. H., Mohanty, A., Hoermann, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4210 · Cited by 256
The Origin of Ovarian Cancer Species and Precancerous Landscape
Shih, I., Wang, Y., & Wang, T. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.09.006 · Cited by 265
Mosaicism in health and disease — clones picking up speed
Forsberg, L. A., Gisselsson, D., & Dumanski, J. P. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.145 · Cited by 261
Circulating tumor DNA as an early cancer detection tool
Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R. C., Mokhnatkin, J. V., Murtaza, M., Gray, S. W., Goetz, L. H., Goel, A., Schork, N. J., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107458 · Cited by 252
Clonal expansion in non-cancer tissues
Kakiuchi, N., & Ogawa, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00335-3 · Cited by 252
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease
Zhu, M., Lu, T., Jia, Y., Luo, X., Gopal, P., Li, L., Odewole, M., Renteria, V., Singal, A. G., Jang, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.026 · Cited by 250
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Perner, F., Perner, C., Ernst, T., & Heidel, F. H. (2019) · Cells · doi:10.3390/cells8080854 · Cited by 248
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla‐Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 259
Libby (2019) · doi:10.1016/j.jacc.2019.06.007 · Cited by 247
Self-citationLoss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo
Jeong, M., Park, H. J., Celik, H., Ostrander, E. L., Reyes, J. M., Guzman, A., Rodriguez, B., Lei, Y., Lee, Y., Ding, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.025 · Cited by 243
Post-zygotic Point Mutations Are an Underrecognized Source of De Novo Genomic Variation
Acuña‐Hidalgo, R., Bo, T., Kwint, M. P., van de Vorst, M., Pinelli, M., Veltman, J. A., Hoischen, A., Vissers, L. E. L. M., & Gilissen, C. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.05.008 · Cited by 246
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
Leal, A., van Grieken, N. C. T., Palsgrove, D. N., Phallen, J. A., Medina, J. E., Hruban, C., Broeckaert, M. A. M., Anagnostou, V., Adleff, V., Bruhm, D. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14310-3 · Cited by 245
Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236
“Analysis of AML and normal subjects suggests mutations in TET2 and in epigenetic regulators can represent early acquiredmutations in ‘‘pre-leukemic’’ stem cells, which subsequently acquire further mutations leading to overt transformation (Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012).”
BackgroundObiorah, I. E., Patel, B. A., Groarke, E. M., Wang, W., Trick, M., Ombrello, A. K., Ferrada, M. A., Wu, Z., Gutierrez‐Rodrigues, F., Lotter, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004976 · Cited by 242
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
Speer, T., Dimmeler, S., Schunk, S. J., Fliser, D., & Ridker, P. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00621-9 · Cited by 251
Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 248
Mas‐Peiró, S., Hoffmann, J., Fichtlscherer, S., Dorsheimer, L., Rieger, M. A., Dimmeler, S., Vasa‐Nicotera, M., & Zeiher, A. M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz591 · Cited by 248
Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis
Osorio, F. G., Huber, A. R., Oka, R., Verheul, M., Patel, S. H., Hasaart, K., de la Fonteijne, L., Varela, I., Camargo, F. D., & van Boxtel, R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.014 · Cited by 246
DNA methylation disruption reshapes the hematopoietic differentiation landscape
Izzo, F., Lee, S. C., Poran, A., Chaligne, R., Gaiti, F., Gross, B., Murali, R. R., Deochand, S. D., Ang, C., Jones, P. W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0595-4 · Cited by 236
Mosaic loss of chromosome Y is associated with common variation near TCL1A
Zhou, W., Machiela, M. J., Freedman, N. D., Rothman, N., Malats, N., Dagnall, C. L., Caporaso, N. E., Teras, L. T., Gaudet, M. M., Gapstur, S. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3545 · Cited by 243
Association of clonal hematopoiesis with chronic obstructive pulmonary disease
Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., et al. (2022) · Blood · doi:10.1182/blood.2021013531 · Cited by 235
Self-citationMeasurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 239
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Churpek, J. E., Pyrtel, K., Kanchi, K., Shao, J., Koboldt, D. C., Miller, C. A., Shen, D., Fulton, R. S., O’Laughlin, M. D., Fronick, C. C., et al. (2015) · Blood · doi:10.1182/blood-2015-04-641100 · Cited by 236
Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231
Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level
Chen, J., Kao, Y.-R., Sun, D., Todorova, T. I., Reynolds, D. M., Narayanagari, S.-R., Montagna, C., Will, B., Verma, A. K., & Steidl, U. G. (2018) · Nature Medicine · doi:10.1038/s41591-018-0267-4 · Cited by 239
Pathogenic mechanisms of somatic mutation and genome mosaicism in aging
Vijg, J., & Dong, X. (2020) · Cell · doi:10.1016/j.cell.2020.06.024 · Cited by 240
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Abegunde, S. O., Buckstein, R., Wells, R. A., & Rauh, M. J. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2017.11.002 · Cited by 230
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 241
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
Xu, Y., Lv, L., Liu, Y., Smith, M. D., Li, W., Tan, X. M., Cheng, M., Li, Z., Bovino, M., Aubé, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129317 · Cited by 230
Merker, J. D., Oxnard, G. R., Compton, C. C., Diehn, M., Hurley, P. A., Lazar, A. J., Lindeman, N. I., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0901-sa · Cited by 227
Pascual-Figal, D. A., Bayés‐Genís, A., Díez-Díez, M., Vicente, Á. H., Andrés, D. J. V., de la Barrera, J., Vázquez, E., Quintas, A., Zuriaga, M. A., Lopez, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.028 · Cited by 229
Cancers make their own luck: theories of cancer origins
Jassim, A., Rahrmann, E. P., Simons, B. D., & Gilbertson, R. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00602-5 · Cited by 236
Kahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850339 · Cited by 225
Self-citationRole of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
Frick, M., Chan, W., Arends, C. M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2184 · Cited by 223
Campia, U., Moslehi, J. J., Amiri‐Kordestani, L., Barac, A., Beckman, J. A., Chism, D. D., Cohen, P., Groarke, J. D., Herrmann, J., Reilly, C. M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000641 · Cited by 229
Adelman, E. R., Huang, H.-T., Roisman, A., Olsson, A., Colaprico, A., Qin, T., Lindsley, R. C., Bejar, R. L., Salomonis, N., Grimes, H. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1474 · Cited by 234
Self-citationGenomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, E. J., Bagg, A., Hasserjian, R. P., Dinardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., et al. (2022) · Blood · doi:10.1182/blood.2022015853 · Cited by 235
Self-citationClonal haematopoiesis and risk of chronic liver disease
Wong, W. J., Emdin, C. A., Bick, A. G., Zekavat, S. M., Niroula, A., Pirruccello, J. P., Dichtel, L. E., Griffin, G. K., Uddin, M. M., Gibson, C. J., et al. (2023) · Nature · doi:10.1038/s41586-023-05857-4 · Cited by 226
Self-citationComprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 225
Association of Clonal Hematopoiesis With Incident Heart Failure
Yu, B., Roberts, M. B., Raffield, L. M., Zekavat, S. M., Nguyen, N. Q., Biggs, M. L., Brown, M. R., Griffin, G. K., Desai, P. M., Correa, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.085 · Cited by 225
Self-citationColchicine in Patients with Chronic Coronary Disease
Lucijanić, M., Javor, E., & Skelin, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2034992 · Cited by 219
CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression
Spencer, D. H., Russler-Germain, D. A., Ketkar, S., Helton, N. M., Lamprecht, T. L., Fulton, R. S., Fronick, C. C., O’Laughlin, M., Heath, S. E., Shinawi, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.021 · Cited by 219
Merlevede, J., Droin, N. M., Qin, T., Meldi, K. M., Yoshida, K., Morabito, M., Chautard, É., Auboeuf, D., Fenaux, P., Braun, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10767 · Cited by 225
Mammalian in vitro gametogenesis
Saitou, M., & Hayashi, K. (2021) · Science · doi:10.1126/science.aaz6830 · Cited by 218
Cordua, S., Kjær, L., Skov, V., Pallisgaard, N., Hasselbalch, H. C., & Ellervik, C. (2019) · Blood · doi:10.1182/blood.2019001113 · Cited by 216
Clonal Hematopoiesis Is Associated With Higher Risk of Stroke
Bhattacharya, R., Zekavat, S. M., Haessler, J., Fornage, M., Raffield, L. M., Uddin, M. M., Bick, A. G., Niroula, A., Yu, B., Gibson, C. J., et al. (2021) · Stroke · doi:10.1161/strokeaha.121.037388 · Cited by 217
Self-citationPtashkin, R. N., Mandelker, D. L., Coombs, C. C., Bolton, K. L., Yelskaya, Z., Hyman, D. M., Solit, D. B., Baselga, J. M., Arcila, M. E., Ladanyi, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2297 · Cited by 213
Aging and the rise of somatic cancer-associated mutations in normal tissues
Risques, R. A., & Kennedy, S. R. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007108 · Cited by 219
Synthetic biomarkers: a twenty-first century path to early cancer detection
Kwong, G. A., Ghosh, S., Gamboa, L., Patriotis, C., Srivastava, S., & Bhatia, S. N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00389-3 · Cited by 218
Biological and clinical consequences of NPM1 mutations in AML
Heath, E. M., Chan, S. M., Minden, M. D., Murphy, T., Shlush, L. I., & Schimmer, A. D. (2017) · Leukemia · doi:10.1038/leu.2017.30 · Cited by 224
Wang, L., Brooks, A. N., Fan, J., Wan, Y., Gambe, R. G., Li, S., Hergert, S., Yin, S., Freeman, S. S., Levin, J. Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.005 · Cited by 213
Self-citationSpatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 227
Volckmar, A., Sültmann, H., Riediger, A. L., Fioretos, T., Schirmacher, P., Endris, V., Stenzinger, A., & Dietz, S. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22517 · Cited by 209
Somatic Evolution in Non-neoplastic IBD-Affected Colon
Ólafsson, S., McIntyre, R. E., Coorens, T. H. H., Butler, T. M., Jung, H., Robinson, P. S., Lee-Six, H., Sanders, M. A., Arestang, K., Dawson, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.036 · Cited by 213
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Tesi, B., Davidsson, J., Voß, M., Rahikkala, E., Holmes, T. D., Chiang, S. C. C., Komulainen‐Ebrahim, J., Gorcenco, S., Nilsson, A. R., Ripperger, T., et al. (2017) · Blood · doi:10.1182/blood-2016-10-743302 · Cited by 209
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212
Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder
Krupp, D. R., Barnard, R. A., Duffourd, Y., Evans, S. A., Mulqueen, R. M., Bernier, R., Rivière, J.-B., Fombonne, E., & O’Roak, B. J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.07.016 · Cited by 204
Monogenic and polygenic inheritance become instruments for clonal selection
Loh, P., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 210
A review of FLT3 inhibitors in acute myeloid leukemia
Zhao, J. C., Agarwal, S., Ahmad, H., Amin, K., Bewersdorf, J. P., & Zeidan, A. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100905 · Cited by 211
Gladyshev, V. N., Kritchevsky, S. B., Clarke, S. G., Cuervo, A. M., Fiehn, O., de Magalhães, J. P., Mau, T., Maes, M., Moritz, R. L., Niedernhofer, L. J., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00150-3 · Cited by 222
Fuster, J. J., Zuriaga, M. A., Zorita, V., MacLauchlan, S., Polackal, M. N., Viana-Huete, V., Ferrer-Pérez, A., Matesanz, N., Herrero-Cervera, A., Sano, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108326 · Cited by 204
Clonal hematopoiesis in acquired aplastic anemia
Ogawa, S. (2016) · Blood · doi:10.1182/blood-2016-01-636381 · Cited by 205
Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment
Yamamoto, R., Wilkinson, A. C., Ooehara, J., Lan, X., Lai, C.-Y., Nakauchi, Y., Pritchard, J. K., & Nakauchi, H. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.03.013 · Cited by 202
NLRP3 inflammasome pathways in atherosclerosis
Baldrighi, M., Mallat, Z., & Li, X. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.027 · Cited by 204
Cell-free DNA analysis in current cancer clinical trials: a review
Cisneros-Villanueva, M., Pérez, L. H., Ríos-Romero, M., Cedro‐Tanda, A., Ruiz-Villavicencio, C. A., Page, K., Hastings, R. K., Fernández-García, D., Allsopp, R. C., Fonseca-Montaño, M. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01696-0 · Cited by 205
Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., Philippis, C. D., Maura, F., Sathiaseelan, V., Tai, Y., Mudie, L. J., et al. (2017) · Leukemia · doi:10.1038/s41375-018-0037-9 · Cited by 211
Pan, W. Q., Zhu, S., Qu, K., Meeth, K. M., Cheng, J., He, K., Ma, H., Liao, Y., Wen, X., Roden, C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.020 · Cited by 202
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
Zekavat, S. M., Lin, S., Bick, A. G., Liu, A., Paruchuri, K., Wang, C., Uddin, M. M., Ye, Y., Yu, Z., Liu, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01371-0 · Cited by 202
Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J., Ianotto, J., Marzac, C., Couedic, J. P. L., Droin, N. M., Chachoua, I., et al. (2015) · Blood · doi:10.1182/blood-2015-07-661983 · Cited by 206
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
Wong, T. N., Miller, C. A., Jotte, M. R. M., Bagegni, N. A., Baty, J., Schmidt, A. P., Cashen, A. F., Duncavage, E. J., Helton, N., Fiala, M. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02858-0 · Cited by 201
Vitamin C in stem cell reprogramming and cancer
Cimmino, L., Neel, B. G., & Aifantis, I. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.001 · Cited by 197
Gontier, G., Iyer, M., Shea, J. M., Bieri, G., Wheatley, E. G., Ramalho-Santos, M., & Villeda, S. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.001 · Cited by 197
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults
Milne, P., Bigley, V., Bacon, C. M., Néel, A., McGovern, N. N., Bomken, S. N., Haniffa, M. A., Diamond, E. L., Durham, B. H., Visser, J., et al. (2017) · Blood · doi:10.1182/blood-2016-12-757823 · Cited by 197
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 201
Genetic and epigenetic heterogeneity in acute myeloid leukemia
Li, S., Mason, C. E., & Melnick, A. M. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.011 · Cited by 195
Therapeutic implications of menin inhibition in acute leukemias
Issa, G. C., Ravandi, F., Dinardo, C. D., Jabbour, E. J., Kantarjian, H. M., & Andreeff, M. (2021) · Leukemia · doi:10.1038/s41375-021-01309-y · Cited by 200
DNMT3A in LeukemiaPreprint
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030320 · Cited by 204
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends, C. M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0047-7 · Cited by 194
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D. T., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19008 · Cited by 197
Self-citationA Revised Perspective of Skeletal Stem Cell Biology
Ambrosi, T. H., Longaker, M. T., & Chan, C. K. F. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00189 · Cited by 196
Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis
Avagyan, S., Henninger, J. E., Mannherz, W. P., Mistry, M., Yoon, J., Yang, S., Weber, M. C., Moore, J. L., & Zon, L. I. (2021) · Science · doi:10.1126/science.aba9304 · Cited by 192
Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer
Fernandez‐Cuesta, L., Perdomo, S. P., Avogbe, P. H., Leblay, N., Delhomme, T. M., Gaborieau, V., Abedi‐Ardekani, B., Chanudet, E., Olivier, M., Zaridze, D. G., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.032 · Cited by 198
Clinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020222 · Cited by 194
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Understanding intrinsic hematopoietic stem cell aging
Mejía-Ramírez, E., & Florian, M. C. (2019) · Haematologica · doi:10.3324/haematol.2018.211342 · Cited by 206
Caye‐Eude, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, É., Nouri, K., Nakhaei‐Rad, S., Dvorský, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3420 · Cited by 197
Kennedy, A. L., Myers, K. C., Bowman, J. R., Gibson, C. J., Camarda, N. D., Furutani, E., Muscato, G. M., Klein, R. H., Ballotti, K., Liu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21588-4 · Cited by 197
Self-citationInnate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
Clinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.264 · Cited by 189
The road ahead in genetics and genomics
McGuire, A. L., Gabriel, S., Tishkoff, S. A., Wonkam, A., Chakravarti, A., Furlong, E. E. M., Treutlein, B., Meissner, A., Chang, H. Y., López-Bigas, N., et al. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0272-6 · Cited by 188
Self-citationMyelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 192
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
Chan, H. T., Chin, Y. M., Nakamura, Y., & Low, S. (2020) · Cancers · doi:10.3390/cancers12082277 · Cited by 192
de Boer, R. A., Hulot, J., Tocchetti, C. G., Aboumsallem, J. P., Ameri, P., Anker, S. D., Bauersachs, J. K., Bertero, E., Coats, A. J. S., Čelutkienė, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2029 · Cited by 188
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021) · Cells · doi:10.3390/cells10010117 · Cited by 195
The Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 202
Metadata
- Authors
- Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., Correa, A., Banahan, B. F., Gabriel, S., Kathiresan, S., Stringham, H. M., McCarthy, M. I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J. G., Neuberg, D., Altshuler, D., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- University of Helsinki (FI)
- University of Southern California (US)
- Helsinki University Hospital (FI)
- Lund University (SE)
- University of Mississippi Medical Center (US)
- University of Michigan (US)
- Centre for Human Genetics (GB)
- Universität für Weiterbildung Krems (AT)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- ORCID
- Jaiswal, Siddhartha
- Fontanillas, Pierre
- Flannick, Jason
- Manning, Alisa
- Mar, Brenton G.
- Lindsley, R. Coleman
- Mermel, Craig H.
- Chavez, Alejandro
- Higgins, John M.
- Kuo, Frank C.
- Kluk, Michael J.
- Kinnunen, Leena
- Koistinen, Heikki A.
- Ladenvall, Claes
- Getz, Gad
- Correa, Adolfo
- Banahan, Benjamin F.
- Gabriel, Stacey
- Kathiresan, Sekar
- Stringham, Heather M.
- McCarthy, Mark I.
- Boehnke, Michael
- Tuomilehto, Jaakko
- Groop, Leif
- Atzmon, Gil
- Wilson, James G.
- Neuberg, Donna
- Altshuler, David
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2488-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4306669
- OpenAlex
- W2149858388
- Cited by
- 4,841
- References
- 48
- Citations by year
- 2026: 423 · 2025: 446 · 2024: 494 · 2023: 521 · 2022: 536 · 2021: 520 · 2020: 454 · 2019: 387 · 2018: 356 · 2017: 301 · 2016: 237 · 2015: 151 · 2014: 6
- FWCI
- 164.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Wellcome Trust (090367, 085475, 098381, 090532, 083948)
- National Institutes of Health (5rc2dk088389-02)
- National Institute on Aging (R01AG042188, P01AG021654, P30AG038072)
- National Heart, Lung, and Blood Institute (R01HL082945, T32HL066987)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (T32CA009216, T32CA009172, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK085526, U01DK085584, DP2DK098087, U01DK085501, U01DK085524, RC2-DK088389, U01DK085545, DK088389, P30DK020572)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- age-related clonal hematopoiesis, somatic mutations, all-cause mortality, coronary artery disease, ischemic stroke, cardiovascular disease, DNMT3A, TET2, ASXL1, peripheral blood, aging
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
